Darolutamide Alone and in Combination With Goserelin in Androgen Receptor-Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial.

J Clin OncolAug 3, 2026 (epub)
Clinical ResearchOncology (Medical)

Susumu Okano, Makoto Tahara, Kiyoaki Tsukahara et al.

✦ AI-curated · Sources linked

In 30 seconds

The phase II DISCOVARY trial evaluated darolutamide, both alone and with goserelin, in patients with androgen receptor-positive unresectable locally advanced or recurrent/metastatic salivary gland carcinoma. The combination therapy showed a confirmed objective response rate of 45.2% and a median progression-free survival of 13.1 months, compared to 8.3% and 5.7 months for monotherapy.

Key findings

  • The combination of darolutamide and goserelin achieved an objective response rate of 45.2%.
  • Monotherapy with darolutamide resulted in a confirmed objective response rate of 8.3%.
  • Median progression-free survival was 13.1 months for the combination cohort versus 5.7 months for monotherapy.
  • Twelve-month overall survival rates were 91.3% for the combination and 87.0% for monotherapy.

Why it matters

This study highlights a potential new treatment strategy for a rare and aggressive cancer with limited options. The combination therapy may offer improved outcomes while preserving quality of life.

Source

PubMed · PMID 42546251

Published in J Clin Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchPreventive Medicine / Public Health

2025 National Guidelines on the Mediterranean Diet: Executive Summary of a Joint Report by Italian Scientific Societies and the National Institute of Health Task Force on Clinical Practice Guidelines.

This systematic review and practice guideline, developed by a multidisciplinary panel using NUTRIGRADE, assessed Mediterranean diet evidence across nine health domains and one economic domain.

Nutr RevNov 12, 2026Read summary
Clinical ResearchOrthopedic Surgery

Prevention of Venous Thromboembolism after Total Hip or Knee Replacement.

This multicenter randomized comparative-effectiveness noninferiority trial compared 30 days of aspirin, warfarin, or rivaroxaban for VTE prophylaxis after elective total hip or knee arthroplasty.

N Engl J MedNov 12, 2026Read summary
Clinical ResearchAnesthesiology

Effect of discontinuing antihypertensives on perioperative hypotension in older patients before non-cardiac surgery: multicentre, randomised, double blind, controlled trial.

This multicentre, randomised, double blind, placebo controlled trial assessed whether withholding ACE inhibitors or ARBs on the morning of surgery reduces perioperative hypotension in older adults undergoing non-cardiac…

BMJNov 11, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.